NewAmsterdam Pharma Co N.V. reported that Futurum B.V., through NAP PoolCo B.V. for the benefit of Chief Scientific Officer and director Johannes Jacob Pieter Kastelein, exercised options for 50,246 ordinary shares on September 30, 2026, at an option exercise price of EUR 1.16392, then sold the same 50,246 shares at a weighted average price of $25.03. The shares were sold in multiple transactions at $25.00 to $25.10 per share under a Rule 10b5-1 trading plan Futurum adopted on March 31, 2026.
After the exercise, Futurum held 344,983 options expiring July 6, 2031. Kastelein also reported a separate direct holding of 53,500 ordinary shares, including 48,166 shares subject to restricted stock unit awards that remain subject to vesting.
NewAmsterdam Pharma Company N.V. (NAMS) announced that the first participant has been dosed in SPINOZA, a Phase 2b trial of obicetrapib in adults with biomarker evidence of preclinical Alzheimer’s disease and no noticeable memory or functional symptoms. The study plans to enroll approximately 400 participants, randomized to obicetrapib 10 mg or placebo for 52 weeks; eligible participants may choose an open-label extension lasting at least 26 weeks. The primary endpoint is change from baseline to Week 52 in plasma p-tau217.
The company reported that a prespecified BROADWAY biomarker analysis found statistically significant lower absolute changes in p-tau217 versus placebo over 12 months in the full analysis set (p=0.025; n=1,535) and ApoE4 carriers (p=0.022; n=367). The analysis used a subset and was not controlled for baseline differences between treatment and placebo populations; statistical analyses were adjusted for baseline biomarker values and age.
NewAmsterdam Pharma Co N.V. (NAMS) is the subject of this Amendment No. 7 to a Schedule 13D, in which multiple Frazier Life Sciences-affiliated funds and entities update their beneficial ownership of the company’s Ordinary Shares, including shares issuable upon exercise of warrants.
Frazier Life Sciences X, L.P. reports beneficial ownership of 7,329,857 Ordinary Shares (including 500,333 shares issuable upon exercise of warrants), representing 6.1% of the class, based on 119,537,169 shares outstanding as of August 3, 2026 plus those warrant shares. Frazier Lifesciences Sponsor LLC reports 3,968,000 shares (3.3%), Frazier Life Sciences Public Fund, L.P. reports 10,424,224 shares (8.7%), Frazier Life Sciences XI, L.P. reports 1,319,923 shares (1.1%), and Frazier Life Sciences XII, L.P. reports 365,231 shares (0.3%). James N. Topper and Patrick J. Heron share voting and investment power over the FLS X and Sponsor positions. The amendment also states that, other than transactions listed in Exhibit 10.1, no reporting person has traded the Ordinary Shares in the past 60 days.
NewAmsterdam Pharma Co N.V. (NAMS) announced that the European Commission granted marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination) to treat primary hypercholesterolaemia and mixed dyslipidaemia, representing the first regulatory approval of obicetrapib worldwide. The authorizations cover all EU Member States, Iceland, Liechtenstein and Norway. The approvals require ongoing safety monitoring, pharmacovigilance, risk-minimization measures and a post-authorization efficacy study using final results from the PREVAIL cardiovascular outcomes trial. Under an existing licensing agreement, Menarini holds exclusive commercialization rights for obicetrapib in Europe and manages regulatory and commercial activities there, while NewAmsterdam is entitled to tiered double-digit royalties and up to €833 million in additional clinical, regulatory and commercial milestones, including milestone payments in the mid-teens of millions of euros triggered by these EC authorizations.
NewAmsterdam Pharma Co N.V. (NAMS) reports that Chief Executive Officer and director Michael H. Davidson purchased 10,000 Ordinary Shares on September 14, 2026 at $22.65 per share in an open-market or private transaction. After this trade he directly holds 792,923 Ordinary Shares, including 163,352 subject to unvested restricted stock unit awards, and is also reported as indirectly holding 285,715 Ordinary Shares through the Michael H. Davidson 2026 Grantor Retained Annuity Trust.
NewAmsterdam Pharma Co N.V. (NAMS) director John W. Smither reported selling 1,600 ordinary shares on September 4, 2026, in an open-market or private transaction at a weighted average price of $25.32 per share. The sale was made to generate proceeds to satisfy his tax obligations related to a prior vesting of restricted stock units and was not reported as made under a Rule 10b5-1 plan. Following this transaction, he reports holding 8,760 ordinary shares, including 8,040 shares subject to restricted stock unit awards that remain subject to vesting.
NewAmsterdam Pharma Co N.V. (NAMS) reported that Vice President, Controller Robert William Gunning received equity compensation awards on September 1, 2026. He was granted options for 14,000 ordinary shares at an exercise price of $24.92 per share, expiring August 31, 2036, plus 3,200 restricted stock units, each representing one ordinary share. The RSUs vest in three equal annual installments beginning September 10, 2026, and 25% of the option shares vest on August 10, 2026, with the remainder vesting in equal monthly installments over the following three years, in each case subject to his continued service. No Rule 10b5-1 trading plan is reported.
NewAmsterdam Pharma Co N.V. (NAMS) is the issuer of ordinary shares that an affiliate, for the account of Kastelein Johannes Jacob Pieter, plans to sell under Rule 144. A notice covers up to 250,000 ordinary shares, with J.P. Morgan Securities LLC acting as broker on Nasdaq.
The filing states these shares are expected to be sold in the next 90 days by Futurum B.V., where John Kastelein is a director. The shares relate to an option exercise from the issuer on 08/24/2026, for cash consideration. Reported outstanding ordinary shares total 119,537,169.
NewAmsterdam Pharma Co N.V. (NAMS) reports that Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V. and NAP PoolCo B.V., exercised options for 125,000 Ordinary Shares and on the same day sold 125,000 Ordinary Shares at a weighted average price of $26.91 per share. The options had an exercise price of EUR 1.16392 per share and were held indirectly through Futurum/PoolCo. After these transactions, Kastelein continues to hold 395,229 options indirectly and 53,500 Ordinary Shares directly, including 48,166 shares subject to RSU vesting. All reported trades were executed under a Rule 10b5-1 trading plan adopted by Futurum B.V. on March 31, 2026.
NewAmsterdam Pharma Co N.V. (NAMS) is named as the issuer in a notice of proposed sale of restricted or control securities under Form 144. An affiliate associated with Johannes Jacob Pieter Kastelein, with sales expected by Futurum B.V., has filed to potentially sell up to 125,000 Ordinary Shares through J.P. Morgan Securities LLC on Nasdaq.
The filing lists an aggregate market value of 3,483,750 for these shares and states that 119,537,169 Ordinary Shares were outstanding. The approximate date of sale is given as 08/24/2026, with the shares acquired via option exercise for cash from the issuer and expected to be sold within the next 90 days.